85 related articles for article (PubMed ID: 34530849)
41. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
42. The masquerading presentation of a systemic anaplastic large cell lymphoma, ALK positive: a case report and review of the literature.
Al-Ahmad S; Maertens V; Libeer C; Schelfhout V; Vanhoenacker F; Boeckx N; Vandevenne M
Acta Clin Belg; 2017 Dec; 72(6):454-460. PubMed ID: 28441913
[TBL] [Abstract][Full Text] [Related]
43. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
[TBL] [Abstract][Full Text] [Related]
44. ALK positive Anaplastic Large Cell Lymphoma of the Thoracic Spine.
Abrego G; García J; Gilbert B; Forseen S; Toscano M
J Radiol Case Rep; 2016 Sep; 10(9):1-12. PubMed ID: 27761194
[TBL] [Abstract][Full Text] [Related]
45. Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival.
Maturu VN; Singh N; Bal A; Gupta N; Das A; Behera D
Lung India; 2016; 33(3):257-66. PubMed ID: 27185988
[TBL] [Abstract][Full Text] [Related]
46. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.
Incharoen P; Reungwetwattana T; Saowapa S; Kamprerasart K; Pangpunyakulchai D; Arsa L; Jinawath A
World J Surg Oncol; 2016 May; 14():139. PubMed ID: 27142166
[TBL] [Abstract][Full Text] [Related]
47. Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.
Lei YY; Yang JJ; Zhong WZ; Chen HJ; Yan HH; Han JF; Yang LL; Wu YL
J Thorac Dis; 2015 Jul; 7(7):1181-8. PubMed ID: 26380734
[TBL] [Abstract][Full Text] [Related]
48. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
Travis WD; Brambilla E; Nicholson AG; Yatabe Y; Austin JHM; Beasley MB; Chirieac LR; Dacic S; Duhig E; Flieder DB; Geisinger K; Hirsch FR; Ishikawa Y; Kerr KM; Noguchi M; Pelosi G; Powell CA; Tsao MS; Wistuba I;
J Thorac Oncol; 2015 Sep; 10(9):1243-1260. PubMed ID: 26291008
[TBL] [Abstract][Full Text] [Related]
49. Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma.
Choi IH; Kim DW; Ha SY; Choi YL; Lee HJ; Han J
J Pathol Transl Med; 2015 Jul; 49(4):310-7. PubMed ID: 26095438
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
51. Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study.
Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
World J Surg Oncol; 2015 Mar; 13():128. PubMed ID: 25890228
[TBL] [Abstract][Full Text] [Related]
52. Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case.
Kaseda K; Watanabe K; Asakura K; Kazama A
World J Surg Oncol; 2015 Feb; 13():74. PubMed ID: 25889062
[TBL] [Abstract][Full Text] [Related]
53. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ; Mok T; Kim DW; Wu YL; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T; Iyer S; Reisman A; Wilner KD; Tursi J; Blackhall F;
N Engl J Med; 2014 Dec; 371(23):2167-77. PubMed ID: 25470694
[TBL] [Abstract][Full Text] [Related]
54. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R
Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012
[TBL] [Abstract][Full Text] [Related]
55. Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts.
Boland JM; Wampfler JA; Jang JS; Wang X; Erickson-Johnson MR; Oliveira AM; Yang P; Jen J; Yi ES
Am J Surg Pathol; 2014 Dec; 38(12):1681-8. PubMed ID: 25007143
[TBL] [Abstract][Full Text] [Related]
56. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.
Wynes MW; Sholl LM; Dietel M; Schuuring E; Tsao MS; Yatabe Y; Tubbs RR; Hirsch FR
J Thorac Oncol; 2014 May; 9(5):631-8. PubMed ID: 24722153
[TBL] [Abstract][Full Text] [Related]
57. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype.
Kim H; Jang SJ; Chung DH; Yoo SB; Sun P; Jin Y; Nam KH; Paik JH; Chung JH
PLoS One; 2013; 8(10):e76999. PubMed ID: 24194854
[TBL] [Abstract][Full Text] [Related]
58. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives.
Desai SS; Shah AS; Prabhash K; Jambhekar NA
Indian J Cancer; 2013; 50(2):80-6. PubMed ID: 23979196
[TBL] [Abstract][Full Text] [Related]
59. Cytologic subtyping of lung adenocarcinoma by using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification.
Rodriguez EF; Monaco SE; Dacic S
Cancer Cytopathol; 2013 Nov; 121(11):629-37. PubMed ID: 23943235
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Weickhardt AJ; Aisner DL; Franklin WA; Varella-Garcia M; Doebele RC; Camidge DR
Cancer; 2013 Apr; 119(8):1467-77. PubMed ID: 23280244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
